Abstract
Objective
The aim of this study was to assess the effect of treatment with a St. John’s wort product (Movina) on cholesterol [total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol] and triglyceride levels in patients with hypercholesterolemia on treatment with a stable dose of atorvastatin in a controlled, randomised, open, crossover interaction study.
Methods
Sixteen patients with hypercholesterolemia treated with a stable dose of atorvastatin (10–40 mg/daily) for at least 3 months were treated with Movina one tablet (containing 300 mg of hypericum perforatum) twice daily and control (a commercially available multivitamin tablet Vitamineral). After a run-in period of 4 weeks, patients were randomised to treatment with either Movina or control for 4 weeks in a crossover design. The atorvastatin dose was kept unchanged during the study period (12 weeks), and assessments of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were performed in the morning with the patients in the fasting condition. The difference between control and active treatment in LDL cholesterol after 4 weeks of treatment was the primary endpoint.
Results
All patients completed the study. The St. John’s wort product significantly increased the serum level of LDL cholesterol compared with control (2.66 mmol/l compared with 2.34 mmol/l, p = 0.004). A significant increase in total cholesterol was also observed (5,10 mmol/l compared with 4.78 mmol/l, p = 0.02). No statistically significant change was observed in HDL cholesterol (1.59 mmol/l and 1.56 mmol/l, p = 0.49) or in triglycerides (1.87 mmol/l and 1.94 mmol/l, p = 0.60). No product-related side effects were reported
Conclusion
An interaction was observed between the studied St.-John’s-wort-containing product and atorvastatin. Physicians and patients should be aware of this interaction and if treatment with a St. John’s wort product is considered necessary, then there may be a need for increasing the dose of atorvastatin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Thomas KJ, Nicholl JP, Coleman P (2001) Use and expenditure on complementary medicine in England: a population based survey. Complement Ther Med 9:2–11
Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G (2004) BMJ 329:27–30
Johne A, Schmider J, Brockmoller J, Stadelmann AM, Stormer E, Bauer S (2002) Decreased plasma levels of amitriptyline and its metabolites on co- medication with an extract from St. John’s wort ( Hypericum perforatum). J Clin Psychopharmacol 22:46–54
Piscitteli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000) Indinavir concentrations and St. John’s wort. Lancet 355:547–548
Ruschizka F, Meier PJ, Turina M, Luscher TF, Noll G (2000) Acute heart transplant rejection due to Saint John’s wort. Lancet 355:548–549
LUPP. Läkemedelsupplysningen i Västra Sverige (lupp.su@vgregion.se)
Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert H, Meier PJ, Fattinger K (2000) St. John’s wort induces intestinal P-glucoprotein/MDR1 and intestinal and hepatic CYP 3A4. Clinical Pharmacology and Therapeutics 68:598–604
Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD (2003) Effects of St. John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290(11):1500–1504
Sugimoto KI, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada KI, Arakawa M, Sakamoto KI, Masada M, Miyamori I, Fujimura A (2001) Different effects of St. John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 70(6):518–524
Holtzman CW, Wiggins BS, Spinler SA (2006) Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 26(11):1601–1607
Shitara Y, Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3- hydroxy-3- methylglutaryl coenzyme A (HMG- CoA) reductase inhibitors: drug- drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112(1):71–105
Sever PS, Dahlöf B, Poulter NR, Wedel H et.al (2004) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower- than- average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial. The Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Drugs 64(2):43–60
Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG et.al for the REVERSAL Investigators (2004) Effect of intensive compared with moderate lipid- lowering therapy on prognosis of coronary atherosclerosis. A randomized controlled trial. JAMA 291(9):1071–1080
LaRosa JC, Grundy SM, Waters DD, Shear C et.al For the Treating to New Target (TNT) Investigators (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl J Med 352(14):1425–1435
Major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) (2002) JAMA 288:2998–3007
Acknowledgements
Financial support for this study was in part received from a research grant from the county of Western Sweden (Västra Götalandsregionen).
Conflict of Interest Statement
The authors of this paper have no conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Andrén, L., Andreasson, Å. & Eggertsen, R. Interaction between a commercially available St. John’s wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol 63, 913–916 (2007). https://doi.org/10.1007/s00228-007-0345-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-007-0345-x